The Future of Ketamine and Temper Disorders In 2019, the FDA and European Commission accepted the usage of an esketamine nasal spready under the model title Spravato to deal with melancholy. Even so, as of 2021, ketamine has not been accepted through the FDA to treat despair or other psychological wellbeing disorders, and thus, the medication is ge… Read More